Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
-
Comparative Study
Trends in health care utilization in British Columbia following public coverage for tiotropium.
To examine the use and cost of health-care services in British Columbia, Canada, before and after public drug coverage for tiotropium bromide. ⋯ Public drug plan coverage for tiotropium in British Columbia reduced out-of-pocket costs for patients and their private insurers. Before versus after time series analysis did not show a reduction in hospitalizations or physician visits, or costs associated with those services.
-
Comparative Study
Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study.
It is common practice for developers of new health care technologies to engage in early dialogue with the major regulatory agencies; such discussions frequently center around the proposed clinical trial designs to support the registration of new interventions and suggestions on their improvement. Pricing and reimbursement agencies are increasingly using the results from health technology assessments to inform their decision making for new technologies. Such assessments are invariably underpinned by the phase 3 clinical trial evidence which may not provide answers to the key questions. ⋯ Although there was some variation in the advice the similarities far outweighed the differences. More experience of early dialogue needs to be accumulated, involving a wider range of pricing and reimbursement agencies and compounds. The conclusion of this study, however, was that early dialogue can be a worthwhile process for all parties and can lead to a common understanding about evidence development for market access.